

Special Issue

Progress in Arrhythmia: Insights in Integrated Care, Anticoagulation Therapy and Precision Medicine

Message from the Guest Editor

Much of the interest of the management of AF has been focused on stroke prevention by using oral anticoagulation therapy and more evidence is needed regarding 1) the efficacy and safety of direct-acting oral anticoagulants (DOACs) compared to vitamin K antagonists (VKAs), particularly in certain subgroups of patients with AF or special situations, and 2) more precise methods to estimate the risk of thromboembolism/bleeding. Indeed, recent international clinical practice guidelines recommend personalized medicine through integrated care and more emphasis on patient-reported outcomes. On the other hand, new technologies open the possibility of precision medicine. Thus, artificial intelligence, biomarkers, the use of smartwatches, patches, and other electronic devices, may lead to a substantial change in the detection and management of AF. This issue aims to shed light on some controversial and scarcely investigated topics in relation to novel approaches that should be considered for detection, stroke prevention, and risk-factor optimization in AF patients. Original researches, systematic reviews, review articles and mini-review articles will be welcomed.

Guest Editor

Dr. José Miguel Rivera-Caravaca

Department of Cardiology, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERCv, Hospital Clínico Universitario Virgen Arrixaca, University of Murcia, 30120 Murcia, Spain

Deadline for manuscript submissions

closed (15 March 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/94028

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).